{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:04:56Z","timestamp":1761894296955},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":4910,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1093\/annonc\/mdl083","type":"journal-article","created":{"date-parts":[[2006,5,11]],"date-time":"2006-05-11T04:20:57Z","timestamp":1147321257000},"page":"1146-1151","source":"Crossref","is-referenced-by-count":7,"title":["An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients"],"prefix":"10.1016","volume":"17","author":[{"given":"S.","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"D'Arco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Celentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Califano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pollio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl083_bb0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(04)01512-8","article-title":"Unanswered questions in acute myeloid leukaemia","volume":"5","author":"Ferrara","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMp030076","article-title":"Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia","volume":"349","author":"Schiffer","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdl083_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdl083_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1040-8428(00)00122-0","article-title":"Acute myeloid leukaemia in the elderly: biology and therapeutic strategies","volume":"39","author":"Pinto","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdl083_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","article-title":"Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia","volume":"115","author":"Wahlin","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdl083_bb0035","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy in acute myeloid leukaemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl083_bb0040","first-page":"998","article-title":"Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia","volume":"89","author":"Ferrara","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdl083_bb0045","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/annonc\/mdi259","article-title":"Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia","volume":"16","author":"Chen","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0050","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.21006","article-title":"Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy","volume":"103","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl083_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10428190400013076","article-title":"Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine","volume":"46","author":"Grigg","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdl083_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00277-003-0650-0","article-title":"Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study","volume":"82","author":"Behringer","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdl083_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02981978","article-title":"Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases","volume":"75","author":"Iwakiri","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdl083_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl083_bb0075","first-page":"2722","volume":"91","author":"Witz","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl083_bb0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl083_bb0085","first-page":"776","article-title":"Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia","volume":"90","author":"Ferrara","year":"2005","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdl083_bb0090","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0095","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2000.18.6.1295","article-title":"CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy","volume":"18","author":"Ferrara","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0100","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl083_bb0105","series-title":"Vol","volume":"38","author":"WHO Handbook for Reporting Results of Cancer Treatment","year":"1979"},{"key":"10.1093\/annonc\/mdl083_bb0110","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.bmt.1704611","article-title":"Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation","volume":"34","author":"Ferrara","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdl083_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdl083_bb0125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid eukemia. A report of the French\u2013American\u2013British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdl083_bb0130","first-page":"1670","volume":"96","author":"Blood","year":"2000","journal-title":"Estey EH. How I treat older patients with AML"},{"key":"10.1093\/annonc\/mdl083_bb0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/107327480301000605","article-title":"Management of acute myelogenous leukemia in the elderly","volume":"10","author":"Rathnasabapathy","year":"2003","journal-title":"Cancer Control"},{"key":"10.1093\/annonc\/mdl083_bb0140","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2003.03.186","article-title":"Assessment of differences in patient populations selected for exclusion from participation in clinical phase III acute myelogenous leukemia trials","volume":"21","author":"Mengis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl083_bb0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.leu.2402782","article-title":"The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial","volume":"17","author":"Keating","year":"2003","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdl083_bb0150","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2141.1999.01379.x","article-title":"Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients","volume":"105","author":"Visani","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdl083_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1034\/j.1600-0609.2002.01651.x","article-title":"De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG)","volume":"68","author":"Ferrara","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdl083_bb0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdi051","article-title":"Secondary acute myeloid leukaemia: results of conventional treatments","volume":"16","author":"Pagano","year":"2005","journal-title":"Experience of GIMEMA trials. Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/7\/1146\/563556\/mdl083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:07:27Z","timestamp":1624442847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419453829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0923753419453829"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl083","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}